864 research outputs found
Activation of ion transport by combined effects of ionomycin, forskolin and phorbol ester on cultured HT-29cl.19A human colonocytes
The differentiated clone 19A of the HT-29 human colon carcinoma cell line was used as a model to study the intracellular electrophysiological effects of interaction of the cAMP, the protein kinase C (PKC) and the Ca2+ pathways, (a) A synergistic effect between ionomycin and forskolin was observed. From intracellular responses it was concluded that the synergistic effect is caused by activation of an apical Cl- conductance by protein kinase A and a basolateral K+ conductance by Ca2+. (b) A transient synergistic effect of ionomycin and the phorbol ester phorbol dibutyrate (PDB) was found. The decrease of the response appeared to be due to PKC-dependent inactivation of the basolateral K+ conductance. The synergism is caused by PKC-dependent increase of the apical Cl- conductance and Ca2+-dependent increase of the basolateral K+ conductance. (c) The effects of carbachol and PDB were not fully additive presumably because of their convergence on PKC activation, (d) Forskolin and P
Monitoring enteral nutrition efficacy in ICU patients: is there a place for the Brix value-derived fraction of enteral formula in gastric residual volume?
status: publishe
Protein tyrosine phosphorylation is involved in osmoregulation of ionic conductances
Using the human Intestine 407 cell line as a model, we investigated a
possible role for tyrosine kinase(s) in regulating the ion efflux pathways
induced by hyposmotic stimulation (regulatory volume decrease, RVD).
Pretreatment of 125I(-)-and 86Rb(+)-loaded cells with the phosphotyrosine
phosphatase inhibitor sodium orthovanadate (200 microM) potentiated
isotope efflux triggered by mild hypotonicity (10-20%) but did not further
increase the efflux in response to more vigorous osmotic stimulation (30%
hypotonicity). The tyrosine kinase inhibitors herbimycin A and genistein
largely reduced the osmoshock-induced efflux in both control and
vanadate-pretreated cells, while not affecting calcium-activated 86Rb+
efflux. Potentiation of the RVD response by vanadate was confirmed by
direct measurements of hypotonicity-induced changes in cell volume.
Hypotonic shock alone triggered a rapid and transient increase in tyrosine
phosphorylation of several proteins as well as phosphorylation of
mitogen-activated protein kinase. Furthermore, the potentiating effects of
vanadate on hypotonicity-induced ion efflux and mitogen-activated protein
(MAP) kinase phosphorylation were mimicked by epidermal growth factor.
Neither vanadate nor epidermal growth factor provoked a RVD-like ionic
response under isotonic conditions. These results indicate that tyrosine
phosphorylation is an essential step in the RVD response and suggest a
novel role of growth factors in the cellular defense against osmotic
stress
Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis
Background: Costâeffective use of biologicals is important. As drug concentrations have been linked to clinical outcomes, monitoring drug concentrations is a valuable tool to guide clinical decisionâmaking. A concentrationâresponse relationship for ustekinumab at trough is uncertain owing to the contradictory results reported.
Objectives: To investigate the relationship between 4âweek postinjection ustekinumab concentrations and clinical response in patients with psoriasis.
Methods: Fortyânine patients with moderateâtoâsevere psoriasis treated with 45 mg or 90 mg ustekinumab every 12 weeks for â„ 16 weeks were included. Ustekinumab serum concentrations and antiâustekinumab antibodies were measured at week 4 after injection and disease severity was assessed by Psoriasis Area and Severity Index (PASI).
Results: At week 4 after injection, a significantly negative correlation was observed between ustekinumab concentrations and absolute PASI score up to 5·9 ÎŒg mLâ1 (Ï = â0·357, P = 0·032). Ustekinumab concentrations were higher in optimal responders (PASI †2) than in suboptimal responders (PASI > 2) (4·0 vs 2·8 ÎŒg mLâ1, P = 0·036). The ustekinumab concentration threshold associated with optimal response was determined to be 3·6 ÎŒg mLâ1 (area under the curve 0·71, sensitivity 86%, specificity 63%). Only one patient (2%) had antiâustekinumab antibodies. Psoriatic arthritis was identified as an independent predictor of higher PASI scores and higher ustekinumab concentrations (P = 0·003 and P = 0·048, respectively).
Conclusions: A concentrationâresponse relationship at week 4 after injection was observed for patients with psoriasis treated with ustekinumab. Monitoring 4âweek postinjection ustekinumab concentrations could timely identify underexposed patients who might benefit from treatment optimization
- âŠ